ABBV stock holds steady below resistance at $213.82 as technical pressure persists: weekly outlook

Traders Union
All News
Financial News
AbbVie slips 0.40% this week

Highlights

AbbVie trades below key medium-term moving averages, reflecting sustained seller pressure despite support from its long-term trend.
Momentum indicators remain mixed to bearish, with weak trend strength and signals suggesting indecision in the short term.
Price is expected to range between $204.00 and $215.00 over the next week, with a downward or sideways move more likely than an advance.

Immunology strength offsets Humira declines as investors weigh policy risks

AbbVie recently reported quarterly results, highlighting robust double-digit sales growth from its immunology drugs Skyrizi and Rinvoq, which are helping to offset declining Humira revenues due to increased biosimilar competition. The company also published new clinical data for Skyrizi in inflammatory arthritis and confirmed its ongoing quarterly dividend payments. Fourth quarter institutional activity included RiverFront Investment Group LLC increasing its holdings by 41.7%, while North Dakota State Investment Board acquired a new stake in the company. Regulatory developments surrounding drug pricing and Medicare negotiations in the US remain important factors for investors.

Mixed weekly momentum as bearish signals meet overbought conditions

Weekly technical analysis indicates ABBV remains under medium-term selling pressure, with the price trading below the MA-20 and MA-50 but well above the MA-200. The nearest resistance is at the MA-50 ($213.82) and Ichimoku Kijun ($214.45), while downside support is anchored by the MA-200 ($176.74). Momentum signals on the weekly chart are mixed: the MACD shows a weak bearish bias, the ADX confirms limited trend strength at 15.40, RSI at 47.49 and CCI at -59.09 lean bearish, but the Stochastic RSI flashes a strong buy signal. Bull/Bear Power is notably overbought at 3.82, and the Awesome Oscillator is neutral; weekly volatility is relatively high at 5.49%.

Continued range-bound outlook as technicals limit upside next week

Looking ahead to the next 5 trading days, ABBV is expected to trade between $204.00 and $215.00, reflecting the current volatility range and indecisive momentum signals. Given that none of the four key weekly indicators suggest a buy, the probability of a strong upward move is less than 20%, keeping the baseline scenario as continued sideways or mild downward price action within the projected range. In a bullish scenario, a break above $215.00 could open space for short-term recovery, but this outcome is unlikely given prevailing technical signals. If ABBV falls below $204.00, a sharper pullback towards lower support levels may occur.

Jainam Mehta, market strategist, sees AbbVie holding above long-term support despite another week of sideways-to-lower action. Fundamental tailwinds from strong Skyrizi and Rinvoq performance offset persistent headline risk from Humira’s decline and drug pricing regulation, yet medium-term technicals remain heavy with price trapped beneath key moving averages. Bearish lean from momentum indicators tempers any breakout hopes, but with volatility high and sentiment indecisive, the setup favors a wait-and-see approach around $204.00–$215.00. "A divergence in oscillator signals tells me to avoid chasing direction this week — if ABBV breaks above $215.00, I’ll consider tactical longs, but otherwise I remain neutral until clear trend strength emerges."

Earlier, analysts noted that AbbVie’s share price faced persistent technical weakness despite robust underlying fundamentals, with limited potential for a near-term rebound unless momentum improved. This outlook remains relevant, as renewed institutional interest and ongoing product performance have yet to trigger a decisive shift, making a sustained move above the key $215.00 resistance level the pivotal indicator to watch for any bullish reversal.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.